EN DE
Watch SpectraCure AB for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SpectraCure AB (SPEC) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of SpectraCure AB stock SEK 0.01, price SEK 0.02, that is 20.3% below the price, quality 20 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0007158118

SA SpectraCure AB logo Thin data Nov 4, 2026

SpectraCure AB

SPEC · ST
Expensive, weak quality

Our calculation puts a fair price 20% below what the stock costs today.

Expensive Growth (revenue 5y +272.5 %/yr in SEK)
Revenue last quarter 43% below a year ago.
Fair value kr 0.0122 · Overvalued
Quality 20/100
Negative free cash flow
Trails peers (1/5)
Narrow moat 9/100 · thin data
Thin data
⚠ Dilution
Watch SpectraCure AB for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 10.92 kr 0.0144 Fair Value kr 0.0122 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range kr 0.0144 – kr 10.92 · the kr 0.0153 price screens above the kr 0.0122 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow SpectraCure in your weekly email

Every Wednesday you see whether SpectraCure is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden.

Show moreShow less

It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.

Stock analysis

SpectraCure AB (SPEC) currently trades at kr 0.0153, while our model-based Fair Value estimate is kr 0.0122, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

SpectraCure AB reported revenue of 868K SEK in FY2025 versus 5.7M SEK in FY2021, a compound −37.7%/yr. Reported net income was −56.1M SEK in FY2025.

Key figures

Market cap 17.4M SEK (≈ $1.8M) Micro · EPS (TTM) kr −0.0900 · Return on equity −48.6% · Return on assets (EBIT) −23.3% (5-year average) · Operating margin −2,680% · Revenue (TTM) −242K SEK · Revenue growth (YoY) −43.3% · Free cash flow −43.7M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 93% below its 52-week high and 6% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −20%, SPEC screens richer than that median.

Fair Value models

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) n/a kr 0.0100 kr 0.0100 50
All 1 models by family
Asset-Based
NCAV (Graham) n/a kr 0.0100 kr 0.0100 50

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 20/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 61
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−95.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+272.5%
Start year 2020 (pandemic). Over 10 years: +1.1% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,359,620.1% (2020) → −6,261.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SPEC screens overvalued: fair value 20% below the price. Compare with Abbott Laboratories, →

Compare SpectraCure AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score 20 · Bottom 25%
Fair Value upside −20.3% · Above median
Profitability
Return on assets −53.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −43.3% · Bottom 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)6 · sector 6
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 17
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs SPEC
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs SPEC
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs SPEC
DexCom, Inc DXCM $79.41 $87.35 +10% vs SPEC
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs SPEC
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs SPEC
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs SPEC
Abbott Laboratories, ABT $109.93 $75.28 −32% vs SPEC
Medtronic plc MDT $101.80 $65.61 −36% vs SPEC
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs SPEC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SpectraCure AB: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SpectraCure AB Fair Value". https://www.fairvalue-calculator.com/stock/SPEC

Frequently asked questions

Is SpectraCure AB (SPEC) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of kr 0.0122 versus a price of kr 0.0153, about 20% lower (overvalued).
What is the fair value of SPEC?
Our model-based fair value for SpectraCure AB is kr 0.0122 (as of Nov 4, 2026), built from audited fundamentals. The current price: kr 0.0153.
What is the quality score of SPEC?
SpectraCure AB has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SpectraCure AB (SPEC)?
Our model-based price target is the fair value of kr 0.0122 (as of Nov 4, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the SpectraCure AB stock forecast for 2026?
Our models put fair value at kr 0.0122, about 20% lower versus a price of kr 0.0153 (overvalued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of SpectraCure AB (SPEC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SpectraCure AB it is kr 0.0122 per share (as of Nov 4, 2026), against a price of kr 0.0153. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is SpectraCure AB stock overvalued or undervalued in 2026?
As of Nov 4, 2026, SPEC trades above its calculated fair value: price kr 0.0153, fair value kr 0.0122, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SPEC?
No. The price is what the market pays today (kr 0.0153); the fair value is what the company's own numbers justify (kr 0.0122). For SpectraCure AB the two are kr 0.0031 per share apart. That gap is exactly why we show both numbers side by side.
How much is SpectraCure AB worth?
The market values SpectraCure AB at about 17.4M SEK (market capitalisation, as of Nov 4, 2026). Per share that is kr 0.0153; our models calculate a fair value of kr 0.0122 per share.
How solid is the balance sheet of SpectraCure AB (SPEC)?
Balance-sheet figures for SpectraCure AB (as of Nov 4, 2026): return on equity −48.6%. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is SPEC from its 52-week high?
SpectraCure AB trades at kr 0.0153, about 93% below its 52-week high of kr 0.2210 and 6% above the low of kr 0.0144 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0122 is for.
Which stocks are comparable to SpectraCure AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SpectraCure AB stock attractive at the current price?
The data as of Nov 4, 2026: price kr 0.0153, calculated fair value kr 0.0122 (−20%), Quality Score 20/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SPEC calculated?
We run SpectraCure AB through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of kr 0.0122 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. SpectraCure AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SpectraCure AB (SPEC)?
The closing price on Nov 6, 2026 was kr 0.0153. Our model-based fair value is kr 0.0122, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SpectraCure AB right now?
Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of SpectraCure AB

How large is the market capitalisation of SpectraCure AB (SPEC)?
The market capitalisation of SpectraCure AB is 17.4M SEK (≈ $1.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of SpectraCure AB (SPEC)?
Earnings per share at SpectraCure AB are kr −0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SpectraCure AB (SPEC)?
The return on equity (ROE) of SpectraCure AB is −48.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SpectraCure AB (SPEC)?
On an EBIT basis the return on assets of SpectraCure AB is −23.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SpectraCure AB (SPEC)?
The operating margin of SpectraCure AB is −2,680% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much revenue does SpectraCure AB (SPEC) generate?
SpectraCure AB generates revenue of −242K SEK (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How fast is revenue growing at SpectraCure AB (SPEC)?
Revenue at SpectraCure AB is growing −43.3% versus a year earlier (3y avg +17.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SpectraCure AB (SPEC) generate?
The free cash flow of SpectraCure AB is −43.7M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does SpectraCure AB (SPEC) hold?
SpectraCure AB holds more cash than debt, 10.5M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch SpectraCure AB in the live analysis

One click puts SpectraCure AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.